TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EXerCise Introduction To Enhance Performance in Dialysis: the EXCITE Study
Brief Summary: To evaluate if a model of intervention based on a low-grade physical program prescribed in the dialysis centre and performed at home can modify the functional capacity and quality of life, reduce the risk of cardiovascular and all-causes mortality, non-fatal cardiovascular events and vascular access failure in dialysis patients.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Nurse-led interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led interviewing | Arm Label: Brief group exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Brief group exercise | Intervention Type: BEHAVIORAL; Name: Nurse-led interviewing; Assigned to Arm(s): Nurse-led interviewing | Intervention Type: OTHER; Name: Brief group exercise; Assigned to Arm(s): Brief group exercise
C: Arm Label: Cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Other: Cognitive training | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: Combined cognitive and exercise training; Type: ACTIVE_COMPARATOR; Interventions: Other: Combined cognitive and exercise training | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive training; Assigned to Arm(s): Cognitive training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise training | Intervention Type: OTHER; Name: Combined cognitive and exercise training; Assigned to Arm(s): Combined cognitive and exercise training
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
Brief Summary: Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.


Options:
A: Arm Label: Pitavastatin 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Arm Label: Pitavastatin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 2 mg, Pitavastatin 4 mg | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Simvastatin 20 mg, Simvastatin 40 mg
B: Arm Label: Pitavastatin; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin
C: Arm Label: pitavastatin 4 mg once daily (QD); Type: EXPERIMENTAL; Interventions: Drug: pitavastatin | Arm Label: pravastatin 40 mg once daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: pravastatin | Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): pitavastatin 4 mg once daily (QD) | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): pravastatin 40 mg once daily (QD)
D: Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Drug Abuse and HIV in Hispanic First Offenders
Brief Summary: The main goal of the proposed study is to evaluate the efficacy of Familias Unidas (United Families), a family-based, ecodevelopmental intervention found to be previously efficacious in preventing and reducing behavior problems, illicit drug use, and unsafe sexual behavior in non-delinquent Hispanic adolescents (Pantin et al., 2003; Prado, Pantin, Briones et al., 2007).

The study hypotheses are as follows:

Hypothesis 1. Familias Unidas will be more efficacious than Treatment as Usual in preventing drug use among Hispanic first offending adolescents or those who are at risk for committing a first time offense over time.

Hypothesis 1a. The effect of Familias Unidas on drug use will be partially mediated by improvements in family functioning.

Hypothesis 2. Familias Unidas will be more efficacious than Treatment as Usual in preventing unsafe sexual behavior among Hispanic first offending adolescents or those who are at risk for committing a first time offense over time.

Hypothesis 2a. The effect of Familias Unidas on unsafe sexual behavior will be partially mediated by improvements in family functioning.

Hypothesis 3. Familias Unidas will be more efficacious than Treatment as Usual in preventing subsequent criminal offenses among Hispanic first offending adolescents or in preventing a first time offense for those at risk for committing a first time offense over time.

Hypothesis 3a. The effect of Familias Unidas on subsequent criminal offenses will be mediated by family functioning.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone-administered supportive-expressive therapy | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone-administered coping improvement therapy | Intervention Type: BEHAVIORAL; Name: Telephone-administered coping improvement therapy; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Telephone-administered supportive-expressive therapy; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Individual therapy; Assigned to Arm(s): 1
B: Arm Label: 1-Day MBSR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MBSR | Arm Label: 8-week MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: MBSR | Intervention Type: BEHAVIORAL; Name: MBSR; Assigned to Arm(s): 1-Day MBSR, 8-week MBSR
C: Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-AD | Arm Label: ETAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ETAU | Intervention Type: BEHAVIORAL; Name: CBT-AD; Assigned to Arm(s): CBT-AD | Intervention Type: BEHAVIORAL; Name: ETAU; Assigned to Arm(s): ETAU
D: Arm Label: Family Function Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Familias Unidas | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Familias Unidas; Assigned to Arm(s): Family Function Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 Infection
Brief Summary: To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: 20mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 48mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 120mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 240mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 240mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 120mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 48mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 20mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: 12 Week Cohort; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: 16 Week Cohort; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort, Control | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort, Control
D: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety Over 48 Weeks of Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler in Adolescents (12 to 17 Years Old) With Moderate Persistent Asthma.
Brief Summary: The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma. Efficacy and safety will be assessed by measuring lung function parameters and evaluating the effects on asthma exacerbations, on Quality of life, on health care resource utilisation an on the number of adverse events.


Options:
A: Arm Label: DAS181 Dry Powder 10 mg qd x 3 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: DAS181 dry powder, formulation F02 | Arm Label: Lactose Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Respitose ML006 (DMV-Fonterra) | Intervention Type: DRUG; Name: DAS181 dry powder, formulation F02; Assigned to Arm(s): DAS181 Dry Powder 10 mg qd x 3 days | Intervention Type: DRUG; Name: Respitose ML006 (DMV-Fonterra); Assigned to Arm(s): Lactose Placebo
B: Arm Label: Ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): Ibuprofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo Respimat | Arm Label: tiotropium low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat low dose | Arm Label: tiotropium high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat high dose | Intervention Type: DRUG; Name: tiotropium Respimat low dose; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: placebo Respimat; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium Respimat high dose; Assigned to Arm(s): tiotropium high dose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
Brief Summary: To demonstrate that import Mesalazine (ASACOL®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (rate of non-emergence of bloody stool), in patients with Ulcerative Colitis in remission, treated for 48 weeks.


Options:
A: Arm Label: Asacol®; Type: EXPERIMENTAL; Interventions: Drug: Asacol® | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine | Intervention Type: DRUG; Name: Asacol®; Assigned to Arm(s): Asacol® | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine
B: Arm Label: Mesalamine (Asacol) Once-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Once-Daily | Arm Label: Mesalamine (Asacol) Twice-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Twice-Daily | Intervention Type: DRUG; Name: Mesalamine Once-Daily; Assigned to Arm(s): Mesalamine (Asacol) Once-Daily | Intervention Type: DRUG; Name: Mesalamine Twice-Daily; Assigned to Arm(s): Mesalamine (Asacol) Twice-Daily
C: Arm Label: TP05 (Mesalazine) 1600mg; Type: EXPERIMENTAL; Interventions: Drug: TP05 | Arm Label: Asacol 400 mg (Tillotts Pharma); Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg | Intervention Type: DRUG; Name: TP05; Assigned to Arm(s): TP05 (Mesalazine) 1600mg | Intervention Type: DRUG; Name: Asacol 400 mg; Assigned to Arm(s): Asacol 400 mg (Tillotts Pharma)
D: Arm Label: Budesonide MMX; Type: EXPERIMENTAL; Interventions: Drug: Budesonide MMX®, Drug: 5-ASA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: 5-ASA | Intervention Type: DRUG; Name: Budesonide MMX®; Assigned to Arm(s): Budesonide MMX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-ASA; Assigned to Arm(s): Budesonide MMX, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise, Physical Function, and Parkinson's Disease
Brief Summary: This randomized, controlled exercise intervention with three groups compares two exercise approaches to standard of care. Supervised interventions are administered for four months, with emphasis on patients adopting exercise habits to continue to exercise for an additional 12 months. Functional outcomes are measured at the completion of the supervised exercise (4 months) as well as 10 and 16 months.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: ParkNet | Arm Label: II; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: ParkNet; Assigned to Arm(s): I | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): II
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Physical Therapy aimed to improve Physical Activity | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy aimed to move safely | Intervention Type: OTHER; Name: Physical therapy aimed to move safely; Assigned to Arm(s): B | Intervention Type: OTHER; Name: Physical Therapy aimed to improve Physical Activity; Assigned to Arm(s): A
C: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi | Arm Label: B. Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength training | Arm Label: C. Low-Impact; Type: OTHER; Interventions: Behavioral: Low-Impact Exercise Control | Intervention Type: BEHAVIORAL; Name: Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): B. Strength training | Intervention Type: BEHAVIORAL; Name: Low-Impact Exercise Control; Assigned to Arm(s): C. Low-Impact
D: Arm Label: Flexibility & Function; Type: EXPERIMENTAL; Interventions: Behavioral: Flexibility and Function exercise program | Arm Label: Aerobic Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise | Arm Label: Home exercise; Type: OTHER; Interventions: Behavioral: Home exercise program | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): Aerobic Exercise | Intervention Type: BEHAVIORAL; Name: Flexibility and Function exercise program; Assigned to Arm(s): Flexibility & Function | Intervention Type: BEHAVIORAL; Name: Home exercise program; Assigned to Arm(s): Home exercise

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laparoscopic vs Abdominal Radical Hysterectomy With Pelvic Lymphadenectomy in Patients With Early Cervical Cancer: A Randomized Clinical Trial
Brief Summary: The purpose of this study is to determine whether laparoscopic radical hysterectomy for early cervical cancer will has decreased postoperative pain intensity compared to abdominal radical hysterectomy with similar postoperative complications and survival rates.


Options:
A: Arm Label: Robotic surgery; Type: EXPERIMENTAL; Interventions: Procedure: Robotic surgery | Arm Label: Abdominal surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal surgery | Intervention Type: PROCEDURE; Name: Robotic surgery; Assigned to Arm(s): Robotic surgery | Intervention Type: PROCEDURE; Name: Abdominal surgery; Assigned to Arm(s): Abdominal surgery
B: Arm Label: Transperitoneal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transperitoneal laparoscopic aortic lymphadenectomy | Arm Label: Extraperitoneal; Type: EXPERIMENTAL; Interventions: Procedure: Extraperitoneal laparoscopic aortic lymphadenectomy | Intervention Type: PROCEDURE; Name: Transperitoneal laparoscopic aortic lymphadenectomy; Assigned to Arm(s): Transperitoneal | Intervention Type: PROCEDURE; Name: Extraperitoneal laparoscopic aortic lymphadenectomy; Assigned to Arm(s): Extraperitoneal
C: Arm Label: Laparoscopic Radical Hysterectomy; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy | Arm Label: Abdominal radical hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal radical hysterectomy | Intervention Type: PROCEDURE; Name: Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy; Assigned to Arm(s): Laparoscopic Radical Hysterectomy | Intervention Type: PROCEDURE; Name: Abdominal radical hysterectomy; Assigned to Arm(s): Abdominal radical hysterectomy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Total Abdominal Radical Hysterectomy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Total Laparoscopic or Robotic Radical Hysterectomy | Intervention Type: PROCEDURE; Name: Total Abdominal Radical Hysterectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Total Laparoscopic or Robotic Radical Hysterectomy; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laparoscopic vs Abdominal Radical Hysterectomy With Pelvic Lymphadenectomy in Patients With Early Cervical Cancer: A Randomized Clinical Trial
Brief Summary: The purpose of this study is to determine whether laparoscopic radical hysterectomy for early cervical cancer will has decreased postoperative pain intensity compared to abdominal radical hysterectomy with similar postoperative complications and survival rates.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: robotic laparoscopic sacrocolpopexy | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Sacral Colpopexy | Intervention Type: PROCEDURE; Name: robotic laparoscopic sacrocolpopexy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Laparoscopic Sacral Colpopexy; Assigned to Arm(s): 1
B: Arm Label: Robotic Surgery; Type: EXPERIMENTAL; Interventions: Procedure: Robotic surgery | Arm Label: Laparoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Surgery | Intervention Type: PROCEDURE; Name: Robotic surgery; Assigned to Arm(s): Robotic Surgery | Intervention Type: PROCEDURE; Name: Laparoscopic Surgery; Assigned to Arm(s): Laparoscopy
C: Arm Label: Laparoscopic Radical Hysterectomy; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy | Arm Label: Abdominal radical hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal radical hysterectomy | Intervention Type: PROCEDURE; Name: Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy; Assigned to Arm(s): Laparoscopic Radical Hysterectomy | Intervention Type: PROCEDURE; Name: Abdominal radical hysterectomy; Assigned to Arm(s): Abdominal radical hysterectomy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Total Abdominal Radical Hysterectomy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Total Laparoscopic or Robotic Radical Hysterectomy | Intervention Type: PROCEDURE; Name: Total Abdominal Radical Hysterectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Total Laparoscopic or Robotic Radical Hysterectomy; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-Term Pre-operative Rehabilitation for Patients With Lung Cancer: A Randomized Trial.
Brief Summary: Patients suffering from non small cell lung cancer(NSCLC), depend upon lung removal to increase their chances of survival. But, this type of surgery cannot be advised to patients with significant heart disease, limited lung fuction or reduced physical fitness. Intensive physical training has been shown to increase aerobic fitness in healthy subjects.

The purpose of this study is to determine the effect of a short term rehabilitation prior to surgery on the post-operative and physiological outcomes for patients undergoing this type of surgery.


Options:
A: Arm Label: Prehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Trimodal prehabilitation management | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trimodal prehabilitation management; Assigned to Arm(s): Prehabilitation group
B: Arm Label: Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Rehabilitation Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation Program; Assigned to Arm(s): Rehabilitation Group
C: Arm Label: rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation | Arm Label: usual care; Type: SHAM_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Rehabilitation; Assigned to Arm(s): rehabilitation | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care
D: Arm Label: Physiotherapy; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physiotherapy; Assigned to Arm(s): Physiotherapy

Answer: C